Strategic Partners A/S (CPH:STRAP)
Denmark · Delayed Price · Currency is DKK | Market Cap | 24.03M -38.3% |
| Revenue (ttm) | n/a |
| Net Income | -3.33M |
| EPS | -82.19 |
| Shares Out | 41.71K |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 10 |
| Average Volume | 13 |
| Open | 562.00 |
| Previous Close | 564.00 |
| Day's Range | 562.00 - 576.00 |
| 52-Week Range | 550.00 - 1,300.00 |
| Beta | 0.08 |
| RSI | 45.76 |
| Earnings Date | Apr 1, 2026 |
About Strategic Partners
Strategic Partners A/S does not have significant operations. Previously, it was engaged in biotech activities. The company was formerly known as Orphazyme A/S and changed its name to Strategic Partners A/S in October 2024. The company was founded in 2009 and is based in Herlev, Denmark. [Read more]
Financial Performance
Financial StatementsNews
Orphazyme closes its global offering, consisting of an initial public offering of American Depositary Shares in the U.S. and a concurrent private placement of ordinary shares in Europe
Orphazyme A/S has today registered a capital increase of new ordinary shares and completed its global offering, consisting of an initial public offering of American Depositary Shares (“ADSs”) in the U...
Orphazyme files final prospectus in connection with a global offering, consisting of initial public offering of American Despositary Shares in the United States and concurrent private placement of ordinary shares in Europe
Orphazyme A/SCompany announcement No. 58/2020 ...
Orphazyme publishes a prospectus regarding listing of 7,616,146 new ordinary shares on Nasdaq Copenhagen in connection with a global offering
Orphazyme A/SCompany announcement No. 57/2020 ...
Orphazyme prices its global offering, consisting of an initial public offering of American Depositary Shares in the U.S. and a concurrent private placement of ordinary shares in Europe
Orphazyme A/SCompany announcement No. 55/2020 ...
Orphazyme A/S provides update on previously announced global offering
Orphazyme A/SCompany announcement No. 54/2020 ...
Orphazyme announces U.S. FDA acceptance and Priority Review of New Drug Application for arimoclomol for Niemann-Pick disease Type C
Orphazyme A/SCompany announcement No. 50/2020 ...
Denmark's Orphazyme files to go public on Nasdaq
Denmark-based Orphazyme A/S has filed to go public in the U.S., but has not yet determined how many shares it will offer.